Upadacitinib and Pain in RA, PsA - Summary - MDSpire

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

  • By

  • Kathryn Wighton

  • February 25, 2026

  • 4 min

Share

Objective:

To evaluate the effectiveness of upadacitinib in reducing pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) compared to adalimumab and placebo.

Approach:
    Key Findings:
    • In RA, upadacitinib showed greater pain reduction than adalimumab and placebo, especially in patients with inflammation.
    • In PsA, pain improvements with upadacitinib were similar to adalimumab in patients with inflammation attenuation.
    • Upadacitinib led to higher rates of inflammation attenuation compared to adalimumab and placebo.
    Interpretation:

    Pain reduction occurred with and without inflammation control, indicating that upadacitinib's direct effects on pain are significant, especially in RA.

    Limitations:
    • Post hoc design of the study.
    • Different trial designs for RA and PsA.
    • Lack of early data in PsA.
    Conclusion:

    Upadacitinib is effective in reducing pain in RA and PsA, with notable direct effects independent of inflammation resolution.

    Sources:

Original Source(s)

Upadacitinib and Pain in RA, PsA

  • by Kathryn Wighton

  • February 25, 2026

Related Content

Fibromyalgia in cancer patients: a systematic review and clinical implications for integrated care

RA Genetics May Reveal Link to Gum Disease

Analysis of East Asian genetic data found a modest inverse association between rheumatoid arthritis susceptibility and periodontitis risk, though researchers said the findings require confirmation in independent cohorts.

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.